Comment on “Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting” Luís Silva Miguel

Comment on «Subclinical atrial fibrillation and the risk of stroke» Diogo Magalhães Cavaco

Reply to the comment on “Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting” João Morais